Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program

Published: 1/02/2018
Nemaura Announces Positive Results for its SugarBEAT® European Clinical Program
Source: WWW.BUSINESSWIRE.COM

LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes today announced positive summary data for its sugarBEAT® European clinical trial program. The summary results were taken from a 25 patient cohort of the previously reported Eur

Read more
Related news
Comment
FACEBOOK